TriangleDISEASE & TREATMENT SETTING
Chronic Myeloid Leukemia
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Chronic Myeloid Leukemia
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Chronic Myeloid Leukemia. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
3 more-specific settings
Study evidence for this setting
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogeno
Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant
Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML
Post Transplant Donor Lymphocyte Infusion
Stem Cell Transplant for Hematological Malignancy
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Indication-specific source history
2006-06-28 · Sprycel (dasatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- event id
- fda-b649ecac7feccbaf
- event date
- 2006-06-28
- event kind
- accelerated-approval
- drug or regimen
- Sprycel (dasatinib)
- source indication text
- Chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib
- match phrase
- chronic myeloid leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-197131992f87c2f02544
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2009-05-21 · Sprycel (dasatinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- event id
- fda-b70c3effba5ac97e
- event date
- 2009-05-21
- event kind
- traditional-approval
- drug or regimen
- Sprycel (dasatinib)
- source indication text
- Chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib
- match phrase
- chronic myeloid leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-197131992f87c2f02544
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2012-10-26 · Synribo (omacetaxine mepesuccinate) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- event id
- fda-c49c357d7d50d2da
- event date
- 2012-10-26
- event kind
- accelerated-approval
- drug or regimen
- Synribo (omacetaxine mepesuccinate)
- source indication text
- Adults with chronic or accelerated phase chronic myeloid leukemia with resistance or intolerance to 2 or more TKIs
- match phrase
- chronic myeloid leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2c3493f3e08411d42498
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2012-12-14 · Iclusig (ponatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- event id
- fda-108760cbb44327a3
- event date
- 2012-12-14
- event kind
- accelerated-approval
- drug or regimen
- Iclusig (ponatinib)
- source indication text
- Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy
- match phrase
- chronic myeloid leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-207b1271c5e76362e54d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2014-02-10 · Synribo (omacetaxine mepesuccinate) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- event id
- fda-224a19b0abbeb906
- event date
- 2014-02-10
- event kind
- traditional-approval
- drug or regimen
- Synribo (omacetaxine mepesuccinate)
- source indication text
- Adults with chronic or accelerated phase chronic myeloid leukemia with resistance or intolerance to 2 or more TKIs
- match phrase
- chronic myeloid leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2c3493f3e08411d42498
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2016-11-28 · Iclusig (ponatinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- event id
- fda-89a66bf821990fc4
- event date
- 2016-11-28
- event kind
- traditional-approval
- drug or regimen
- Iclusig (ponatinib)
- source indication text
- Adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia resistant or intolerant to TKI therapy or or Philadelphia chromosome positive acute lymphoblastic leukemia resistant or intolerant to prior TKI therapy
- match phrase
- chronic myeloid leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-207b1271c5e76362e54d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-10-29 · Scemblix (asciminib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- event id
- fda-26414c60d9721649
- event date
- 2021-10-29
- event kind
- accelerated-approval
- drug or regimen
- Scemblix (asciminib)
- source indication text
- Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
- match phrase
- chronic myeloid leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-1b440f2c1ffd9a94caa9
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-10-12 · Scemblix (asciminib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- event id
- fda-1e4abc0adf4a73f8
- event date
- 2022-10-12
- event kind
- traditional-approval
- drug or regimen
- Scemblix (asciminib)
- source indication text
- Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
- match phrase
- chronic myeloid leukemia
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-1b440f2c1ffd9a94caa9
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-10-29 · Scemblix (asciminib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- event id
- fda-1b7c1d04430bc918
- event date
- 2024-10-29
- event kind
- accelerated-approval
- drug or regimen
- Scemblix (asciminib)
- source indication text
- Treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).
- match phrase
- chronic myeloid leukemia
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f95ec17446197e3c8811
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-chronic-myeloid-leukemia
- binding id
- ncit-C3174
- source collection
- ncit-concept
- source key
- C3174
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice